文献速递骨软组织肉瘤与黑色素瘤

NRAS突变与NRAS野生型黑色素瘤患者的免疫检查点抑制:基于前瞻性皮肤癌登记ADOREG中637例患者的多中心皮肤肿瘤协作组研究

Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.
PubMed 文献 · Eur J Cancer · 2023-04-24

该研究基于前瞻性多中心皮肤癌登记ADOREG,纳入2014年6月至2020年5月接受一线免疫检查点抑制剂(ICI)治疗的晚期不可切除黑色素瘤患者,比较NRAS突变型与野生型的疗效。637例BRAF野生型患者中310例(49%)存在NRAS突变。NRAS状态不影响抗PD1单药或抗PD1联合抗CTLA4治疗的PFS和OS,ORR相似,PD-L1表达与NRAS状态无关。

要点

  • 637例BRAF野生型黑色素瘤患者中49%存在NRAS突变,Q61R和Q61K最常见。
  • NRAS状态不影响抗PD1单药或联合抗CTLA4治疗的PFS和OS。
  • NRAS野生型与突变型患者ORR相似,PD-L1表达与NRAS状态无关。

核心结论

  • 在接受以抗PD1为基础的ICI治疗的患者中,PFS和OS不受NRAS突变状态影响。
  • NRAS野生型和NRAS突变型患者观察到相似的ORR。
  • 肿瘤PD-L1表达与NRAS突变状态不相关。

研究设计与样本

  • 前瞻性多中心皮肤癌登记ADOREG研究,纳入2014年6月至2020年5月接受一线ICI治疗的晚期不可切除、NRAS突变状态已知的黑色素瘤患者637例。
  • 采用Kaplan-Meier法分析生存,多因素Cox模型分析与PFS和OS相关的因素。

主要发现

  • 637例BRAF野生型患者中,310例(49%)存在NRAS突变,其中Q61R占41%、Q61K占32%。
  • NRAS突变型黑色素瘤更常见位于下肢和躯干(p=0.001),结节型为最常见亚型(p<0.0001)。
  • 抗PD1单药治疗:NRAS突变型2年PFS为39%(95%CI 33-47),NRAS野生型为41%(95%CI 35-48);NRAS突变型2年OS为54%(95%CI 48-61),NRAS野生型为57%(95%CI 50-64),两组间无显著差异。
  • 抗PD1联合抗CTLA4治疗:NRAS突变型2年PFS为54%(95%CI 44-66),NRAS野生型为53%(95%CI 41-67);NRAS突变型2年OS为58%(95%CI 49-70),NRAS野生型为62%(95%CI 51-75),两组间无显著差异。
  • 抗PD1治疗ORR在NRAS野生型为35%、NRAS突变型为26%;联合治疗ORR在NRAS野生型为34%、NRAS突变型为32%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melanomas frequently harbour somatic mutations in BRAF (40%) or NRAS (20%). Impact of NRAS mutations on the therapeutic outcome of immune checkpoint inhibitors (ICI) remains controversial. Potential correlation of the NRAS mutational status and programmed cell death ligand-1 (PD-L1) expression in melanoma is unknown. PATIENTS AND METHODS: Advanced, non-resectable melanoma patients with known NRAS mutation status treated with first-line ICI between 06/2014 and 05/2020 in the prospective multicenter skin cancer registry ADOREG were included. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) according to NRAS status were analysed. A multivariate Cox model was used to analyse factors associated with PFS and OS; survival was analysed using the Kaplan-Meier approach. RESULTS: Among 637 BRAF wild-type patients, 310 (49%) had an NRAS mutation with Q61R (41%) and Q61K (32%). NRAS-mutated (NRASmut) melanomas were significantly more often located on the lower extremities and trunk (p = 0.001); nodular melanoma was the most common subtype (p < 0.0001). No significant differences were found for PFS and OS for anti-PD1 monotherapy (2-year PFS 39%, [95% confidence interval (CI), 33-47] in NRASmut patients and 41% [95% CI, 35-48] in NRAS-wild type (NRASwt) patients; 2-year OS was 54% [95% CI, 48-61] in NRASmut patients and 57% [95% CI, 50-64] in NRASwt patients) and anti-PD1 plus anti-CTLA4 therapy between both cohorts (2-year PFS was 54% [95% CI, 44-66] in NRASmut patients and 53% [95% CI, 41-67] in NRASwt patients; 2-year OS was 58% [95% CI, 49-70] in NRASmut patients and 62% [95% CI, 51-75] in NRASwt patients). The ORR to anti-PD1 was 35% for NRASwt patients and 26% for NRASmut patients and 34% compared to 32% for combinational therapy. Data on PD-L1 expression was available in 82 patients (13%). PD-L1 expression (>5%) was not correlated to NRAS mutational status. In multivariate analysis, elevated lactate dehydrogenase, Eastern Cooperative Oncology Group performance status ≥ 1, and brain metastases were significantly associated with a higher risk of death in all patients. CONCLUSIONS: The PFS and OS were not affected by NRAS mutational status in patients treated with anti-PD1-based ICI. Similar ORR was seen in NRASwt and NRASmut patients. Tumour PD-L1 expression did not correlate with NRAS mutational status.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zaremba A, Mohr P, Gutzmer R, et al. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. Eur J Cancer. 2023. PMID: 37245442. doi:10.1016/j.ejca.2023.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。